EC Number   |
Disease |
PubMed ID  |
Title of Publication |
Category |
Confidence Level |
|---|
   3.2.1.113 | Mania |
8744 |
Rebound phenomena in manic patients following physostigmine. Preliminary observations. |
unassigned |
0 |
| 3.2.1.113 | Mania |
12646 |
Comparison of the therapeutic effect of lithium and neuroleptic treatment (haloperidol, octoclothepin, oxyprothepin) in mania patients [proceedings]. |
therapeutic application
unassigned |
4
0 |
| 3.2.1.113 | Mania |
17307 |
Bromocriptine in treating mania. |
therapeutic application
unassigned |
1
0 |
| 3.2.1.113 | Mania |
20015 |
The switch process in manic-depressive psychosis. |
causal interaction
diagnostic usage
ongoing research
therapeutic application |
3
2
1
2 |
| 3.2.1.113 | Mania |
25035 |
Clinical and biochemical heterogeneity of depressive disorders. |
therapeutic application
unassigned |
1
0 |
| 3.2.1.113 | Mania |
34329 |
Treatment of tardive dyskinesia and mania with RBC lithium determinations. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
1
4
0 |
| 3.2.1.113 | Tardive Dyskinesia |
34329 |
Treatment of tardive dyskinesia and mania with RBC lithium determinations. |
causal interaction
diagnostic usage
therapeutic application
unassigned |
2
1
4
0 |
| 3.2.1.113 | Mania |
35924 |
[Contribution of biology to nosology of depressive states. Neurochemical, endocrine and genetic factors (author's transl)] |
unassigned |
0 |
| 3.2.1.113 | Mania |
36866 |
Lithium in the treatment of mania: comparisons with neuroleptics. |
causal interaction
therapeutic application
unassigned |
1
4
0 |
| 3.2.1.113 | Mania |
37855 |
Pharmacological studies on 3-]gamma-(p-fluorobenzoyl)propyl]-2,3,4,4a,5,6-hexahydro-1-(H)-pyrazino ]1,2-a] quinoline hydrochloride (compound 69/183). Part III: Assessment of tranquillising activity. |
unassigned |
0 |
